Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia

Cancer

Volumn 119, Issue 1, 2013, Pages 115-125

  Zhang, Ying ^a   Zhang, Yingmei ^a   Zhang, Zhuo ^a   Li, Jinmei ^a   Li, Limin ^a   Han, Xueying ^a   Han, Lina ^a   Hu, Longhu ^a   Wang, Shuye ^a   Zhao, Yanhong ^a   Li, Xiaoxia ^a   Fan, Shengjin ^a   Lv, Chengfang ^a   Li, Yinghua ^a   Su, Yanhua ^a   Zhao, Hui ^a   Zhang, Xin ^a   Zhou, Jin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

acute promyelocytic leukemia; arsenic trioxide; elderly patient; first line treatment

Indexed keywords

ALLOPURINOL; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; HYDROXYUREA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; INCIDENCE; LEUKOCYTOSIS; LIVER DYSFUNCTION; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; SINUS TACHYCARDIA; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; PROGNOSIS; RECURRENCE;

EID: 84872822747     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27650     Document Type: Article

References (20)

1. Adès L, Chevret S, De Botton S, et al. Outcome of acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia. 2005; 19: 230-233.
2. Sanz MA, Vellenga E, Rayõn C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood. 2004; 104: 3490-3493.
3. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH,. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999; 93: 4131-4143.
4. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999; 94: 1192-1200.
5. Mandelli F, Latagliata R, Avvisati G, et al. Italian GIMEMA Cooperative Group. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia. 2003; 17: 1085-1090.
6. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010; 28: 3866-3871.
7. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006; 107: 2627-2632.
8. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol. 2006; 17: 131-134.
9. Tallman MS,. Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal. Leuk Lymphoma. 2009; 50: 12-13.
10. Guha Mazumder DN,. Chronic arsenic toxicity & human health. Indian J Med Res. 2008; 128: 436-447.
11. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010; 115: 1697-1702.
12. Mathew A, Pandey M,. Attributing death to cancer: cause-specific survival estimation. J Postgrad Med. 2002; 48: 322-326.
13. Kim HT,. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007; 13 (2 Pt 1): 559-565.
14. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96: 1247-1253.
15. Zhang TD,. Treatment of acute granulocytic leukemia with "Ai ling No. 1"-clinical analysis and experimental research [in Chinese]. Zhong Xi Yi Jie He Za Zhi. 1984; 4: 19-20.
16. Disperati P, Minden MD, Gupta V, et al. Acute promyelocytic leukemia in patients aged 70 years and over-a single center experience of unselected patients. Leuk Lymphoma. 2007; 48: 1654-1658.
17. Ferrara F, Finizio O, D'Arco A, Mastrullo L, Cantore N, Musto P,. Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients. Anticancer Res. 2010; 30: 967-971.
18. Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia. 2002; 16: 617-622.
19. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001; 98: 266-271.
20. Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001; 97: 1514-1516.